RICERCA ITALIANA     

FIRB simili:

• 1 - Disegno e sintesi di composti per l'inibizione di enzimi coinvolti in meccanismi specifici di controllo della proliferazione delle cellule tumorali.
• 2 - Sviluppo di molecole innovative in grado di curare malattie neurodegenerative e neuroinfiammatorie.
• 3 - Il riconoscimento molecolare nelle interazioni proteina-ligando, proteina-proteina e proteina superficie: sviluppo di approcci sperimentali e computazionali integrati per lo studio di sistemi di interesse farmaceutico
• 4 - Approcci combinati di terapia genica nel trattamento del glioblastoma
• 5 - Molecole innovative ad attività antiflogistica ed antitumorale prodotte con metodologie chimiche avanzate
• 6 - BILANCIO OSPITE-TUMORE NELLA TERAPIA MEDICA DELLE NEOPLASIE: RUOLO DI NF-kB
• 7 - Progettazione, sintesi e screening biologico con metodi ad alta resa di librerie combinatoriali di molecole sviluppate a partire da unità strutturali originali, per applicazioni in campo terapeutico e diagnostico
• 8 - Metodologie Innovative di Risonanza Magnetica (RM) in Patologie Tumorali e Cardiovascolari
• 9 - Il sistema di trasduzione del segnale Ca2+: dalle molecole alle funzioni
• 10 - Meccanismi molecolari della morte cellulare e loro implicazione in patologia umana

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • BIOCHIMICA
• Area scientifico disciplinare: Scienze mediche
  • MICROBIOLOGIA E MICROBIOLOGIA CLINICA
  • MALATTIE INFETTIVE

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • SUGARS; DERIVATIVES THEREOF (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C121/36; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; sugar and starch industry C13)
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]
    • THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Classificazione geografica

• Regione: Sardegna

Bibliografia

1. Lavanchy, D., R. Purcell, F. B. Hollinger, C. Howard, A. Alberti, M. Kew, G. Dusheiko, M. Alter, E. Ayoola, P. Beutels, R. Bloomer, B. Ferret, R. Decker, R. Esteban, O. Fay, H. Fields, E. C. Fuller, P. Grob, M. Houghton, N. Leung, S. A. Locarnini, H. Margolis, A. Meheus, T. Miyamura, M. K. Mohamed, B. Tandon, D. Thomas, H. T. Head, A. U. Toukan, P. Van Damme, A. Zanetti, R. Arthur, M. Couper, R. D'Amelio, J. C. Emmanuel, K. Esteves, P. Gavinio, E. Griffiths, Z. Hallaj, C. C. Heuck, D. L. Heymann, S. E. Holck, M. Kane, L. J. Martinez, F. Meslin, I. S. Mochny, A. Ndikuyeze, A. M. Padilla, G. M. Rodier, C. Roure, F. Savage, and G. Vercauteren. 1999. Global surveillance and control of hepatitis C. J. Viral Hepat. 6:35-47.
2. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
3. Zeuzem, S., G. Teuber, J. H. Lee, B. Ruster, and W. K. Roth. 1996. Risk factors for the transmission of hepatitis C. J. Hepatol. 24:3-10.
4. Dutta, U., J. Kench, K. Byth, M. H. Khan, R. Lin, C. Liddle, and G. C. Farrell. 1998. Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Hum. Pathol. 29:1279-1284.
5. Kasai, Y., S. Takeda, and H. Takagi. 1996. Pathogenesis of hepatocellular carcinoma: a review from the viewpoint of molecular analysis. Semin. Surg. Oncol. 12:155-159.
6. Pontisso, P., C. Belluco, R. Bertorelle, L. De Moliner, L. Chieco Bianchi, D. Nitti, M. Lise, and A. Alberti. 1998. Hepatitis C virus infection associated with human hepatocellular carcinoma: lack of correlation with p53 abnormalities in Caucasian patients. Cancer 83:1489-1494.
7. Gubler, D. J. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480-496.
8. World Health Organization. 1997. Dengue bulletin. Bull. W. :1-15.
9. World Health Organization. 1993. Monograph on dengue/dengue hemorrhagic fever. Regional publication, SEARO no. 22. World Health Organization, Geneva, Switzerland.
10. Kurane, I., A. L. Rothman, P. G. Livingston, S. Green, S. J. Gagnon, J. Janus, B. L. Innis, S. Nimmannitya, A. Nisalak, and F. A. Ennis. 1994. Immunopathologic mechanisms of dengue hemorrhagic fever and dengue shock syndrome. Arch. Virol. Suppl. 9:59-64.
11. Ramirez Ronda, C. H., and C. D. Garcia. 1994. Dengue in the Western Hemisphere. Infect. Dis. Clin. North Am. 8:107-128.
12. Han, L. L., F. Popovici, J. P. Alexander, V. Laurentia, L. A. Tengelsen, C. Cernescu, H. E. Gary, N. Ion Nedelcu, G. L. Campbell, and T. F. Tsai. 1999. Risk factors for West Nile virus infection and meningoencephalitis, Romania, 1996. J. Infect. Dis. 179:230-233.
13. Tsai, T. F., F. Popovici, C. Cernescu, G. L. Campbell, and N. I. Nedelcu. 1998. West Nile encephalitis epidemic in southeastern Romania. Lancet 352:767-771.
14. Davis, G. L. 1999. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Semin. Liver Dis. 19(Suppl. 1):49-55.
15. Davis, G. L., R. Esteban Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M. H. Ling, and J. Albrecht. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1493-1499.
16. Lau, D. Y., D. E. Kleiner, M. G. Ghany, Y. Park, P. Schmid, and J. H. Hoofnagle. 1998. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 28:1121-1127.
17. Davis, G. L., L. A. Balart, E. R. Schiff, K. Lindsay, H. C. Bodenheimer, Jr., R. P. Perrillo, W. Carey, I. M. Jacobson, J. Payne, J. L. Dienstag, et al. 1990. Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group. J. Hepatol. 11(Suppl. 1):S31-S35.
18. Martinot Peignoux, M., N. Boyer, M. Pouteau, C. Castelnau, N. Giuily, V. Duchatelle, A. Auperin, C. Degott, J. P. Benhamou, S. Erlinger, and P. Marcellin. 1998. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J. Hepatol. 29:214-223.
19. Huggins, J. W. 1989. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 11(Suppl. 4):S750-S761.
20. Chen, Y., T. Maguire, and R. M. Marks. 1996. Demonstration of binding of dengue virus envelope protein to target cells. J. Virol. 70:8765-8772.
21. Pileri, P., Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca, A. J. Weiner, M. Houghton, D. Rosa, G. Grandi, and S. Abrignani. 1998. Binding of hepatitis C virus to CD81. Science 282:938-941.
22. Pickering, J. M., H. C. Thomas, and P. Karayiannis. 1997. Predicted secondary structure of the hepatitis G virus and GB virus-A 5'untranslated regions consistent with an internal ribosome entry site. J. Viral Hepat. 4:175-184.
23. Poole, T. L., C. Wang, R. A. Popp, L. N. Potgieter, A. Siddiqui, and M. S. Collett. 1995. Pestivirus translation initiation occurs by internal ribosome entry. Virology 206:750-754.
24. Tsukijama, K.K., N,Iizuka, M. Kohara, and A. Nomoto. 1992. Internal ribosome entry site within hepatitis C virus RNA. J. Virol. 66: 1476-1483.
25. Behrens, S. E., L. Tomei, and R. De Francesco. 1996. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15:12-22.
26. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:649-688.
27. Westaway, E. G. 1987. Flavivirus replication strategy. Adv. Virus Res. 33:45-90.
28. Cai, W., E. Maier, N. Morin, E. Ilan,J. Schwedesl, P. Cai, K. Hubermanl, S. Dagan, R. Rondo, A. Heguy, and S. Mounir. 1998. Discovery of anti-HCV IRES compound, general session I, presentation 5. In Symposium on Emerging Therapies for Chronic Viral Hepatitis.
29. Mori, A., K. Yamada, J. Kimura, T. Koide, S. Yuasa, E. Yamada, and T. Miyamura. 1996. Enzymatic characterization of purified NS3 serine proteinase of hepatitis C virus expressed in Escherichia coli. FEBS Lett. 378:37-42.
30. Failla, C., L. Tomei, and R. De Francesco. 1994. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 68:3753-3760.
31. Kim, J. L., and P. R. Caron. 1998. Crystal structure of hepatitis C NS3 RNA helicase reveals a possible enzyme mechanism and suggests multiple drug binding sites. Int. Antiviral News 6:26-28.
32. Wengler, G., and G. Wengler. 1993. The NS 3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology 197:265-273.
33. Koonin, E. V. 1993. Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus. J. Gen. Virol. 74:733-740.
34. Balzarini, J., A. Karlsson, L. Wang, C. Bohman, K. Horska, I. Votruba, A. Fridland, A. Van Aerschot, P. Herdewijn, and E. De Clercq. 1993. Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J. Biol. Chem. 268:24591-24598.
35. Askari, F. K., and W. M. McDonnell. 1996. Antisense-oligonucleotide therapy. N. Engl. J. Med. 334:316-318.
36. De Clercq, E. 1993. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv. Virus Res. 42:1-55.
37. Rice, C. M. 1996. Flaviviridae: the viruses and their replication, p. 931-960. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 1. Lippincott-Raven Publishers, Philadelphia, Pa.

Parole Chiave

analoghi nucleotidi; Flaviviridae; Terapeutica